No Detail Found!

Sustained virological response to antiviral drugs in treatment of different genotypes of HCV cirrhotic patients

Author(s)
Amin Ullah Department of Health and Biological sciences, Abasyn University,Peshawar,Pakistan
Aqsa Maryam Nawaz Sharif Medical College, Gujrat, Pakistan
Ghaffarul Malik Nawaz Sharif Medical College, Gujrat, Pakistan
Hira Hameed Institute of Microbiology, University of Agriculture, Faisalabad, Pakistan
Kifayat Hussain Department of Medical Laboratory Technology, Rehman College of Allied Health Sciences, Peshawar, Pakistan
Junaid Ahmad Department of Health and Biological sciences, Abasyn University, Peshawar, Pakistan
Ihteshamul Haq Department of Biomedical Science, Universita Degli Studi Di, Sassari, Italy
Mohsina Haq Department of Microbiology, Peshawar Medical College (Ripha International University, Islamabad), Peshawar, Pakistan
Reem M Aljowaie Department of Botany and Microbiology, College of Science, King Saud University,P.O. 2455, Riyadh 11451,Saudi Arabia
Elsayed Mohsen Abougazia Faculty of Medicine, Alexandria University,Alexandria Governorate,Egypt
Tse-Wei Chen Department of Materials, Imperial College London,London,United Kingdom
Jamshaid Ahmad Centre of Biotechnology and Microbiology, University of Peshawar,Peshawar,Pakistan
Kashif Bashir Department of Health and Biological sciences, Abasyn University,Peshawar,Pakistan
Laiba Ahmad Khyber Medical College (KMC), Peshawar, Pakistan
Bashir Ahmad Institiute of Biotechnology and Microbiology, Bacha Khan University Charsada, Peshawar, Pakistan
Abstract
Cirrhosis and liver cancer are both caused by hepatitis C virus (HCV) infection of the liver. Patients with HCV cirrhosis may be treated with one of many antiviral medications, depending on their specific genotype. Samples of cirrhotic HCV were obtained from 190 people at the Khyber Teaching Hospital and the Hayatabad Medical Complex in Peshawar, Pakistan. Multiplex and real-time PCR were used to assess the genotypes and viral loads of the samples, respectively. Sixty patients were given sofosbuvir plus daclatasvir with ribavirin, while the remaining 56 patients were given sofosbuvir with ribavirin for a period of 12-24 weeks. LFTs were also tracked both before and after therapy. Group I (sofosbuvir + daclatasvir) had a sustained virological response of 82.70 percent. Group II (sofosbuvir + daclatasvir with ribavirin) had an 86% sustained virological response, whereas group III (84% sustained virological response) received only ribavirin. When compared to other genotypes, genotype 3 showed the most impressive sustained virologic response (SVR) to the antiviral medicines. Based on the results of this trial, we propose sofosbuvir + daclatasvir ribavirin for the treatment of cirrhotic patients with various HCV genotypes since it produces the greatest sustained virological response.
Publication Details
Page(s) 1009-1015
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 36, Issue: S3, Year: 2023

Request the full text from PASTIC

Keywords
Cirrhosis, genotypes, HCV, Sofosbuvir, ribavirin, RT-PCR, Daclatasvir
References
Bartenschlager R,Baumert TF,Bukh J,Houghton M,Lemon SM,Lindenbach BD,Lohmann V,Moradpour D,Pietschmann T,Rice CM,Thimme R CM .2018 .Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies. Virus Res., 15(248) : 53-62.
Calvaruso V,Mazzarelli C,Milazzo L,Badia L,Pasulo L,Guaraldi G,Lionetti R,Villa E,Borghi V,Carrai P,Alberti A .2019 .Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program. Sci. Rep, 9(1) : 585.
Carrion AF .2017 .Treatment of HCV in individuals with decompensated cirrhosis. J. Liver Res. Disord. Ther., 3(4) : 00056.
Charlton MR,Gane EJ,Manns MP,Brown RS,Curry MP,Kwo PY,Fontana RJ,Gilroy R,Teperman LW,Muir AJ,McHutchison JG .2013 .Sofosbuvir and ribavirin for the treatment of established recurrent hepatitis c infection after liver transplantation: preliminary results of a prospective, multicenter study: LB-2. , 58(6) : 1378A.
Di Pascoli M,Ceranto E,De Nardi P,Donato D,Gatta A,Angeli P,Pontisso P .2017 .Hospitalizations due to cirrhosis: Clinical aspects in a large cohort of Italian patients and cost analysis report. Digestive Dis, 35(5) : 433-438.
.2016 .EASL recommendations on treatment of hepatitis C. J. , 66(1) : 153-194.
Foster GR,Afdhal N,Roberts SK,Brau N,Gane EJ,Pianko S,Lawitz E,Thompson A,Shiffman ML,Cooper C,Towner WJ C .2015 .Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N. Engl. J. Med, 373(27) : 2608-2617.
Ilyas JA,Vierling JM .2011 .An overview of emerging therapies for the treatment of chronic hepatitis C. C. Clin. , 15(3) : 515-536.
Janiak M,Caraballo Cortés K,Perlejewski K,KubickaRussel D,Grabarczyk P,Demkow U,Radkowski M U .2018 .Next-generation sequencing of hepatitis C virus (HCV) mixed-genotype infections in anti-HCVnegative blood donors. Phys. Ther, : 65-71.
Lanini S,Ustianowski A,Pisapia R,Zumla A,Ippolito G .2019 .Viral hepatitis: Etiology, epidemiology, transmission, diagnostics, treatment and prevention. Infect. Dis. Clin., 33(4) : 1045-1062.
Liu CH,Su TH,Liu CJ,Hong CM,Yang HC,Tseng TC,Chen PJ,Chen DS,Kao JH,Gastroenterol JH .2019 .Sofosbuvir based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection. , 34(9) : 1620-1625.
Majumdar A,Kitson MT,Roberts SK .2016 .Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. , 43(12) : 1276-1292.
Pellicelli AM,Montalbano M,Lionetti R,Durand C,Ferenci P,D'Offizi G,Knop V,Telese A,Lenci I,Andreoli A,Zeuzem S A .2014 .Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late. Dig. Liver Dis, 46(10) : 923-927.
Pol S,Ghalib RH,Rustgi VK,Martorell C,Everson GT,Tatum HA,Hezode C,Lim JK,Bronowicki JP,Abrams GA,Brau N GA .2012 .Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. The Lancet Inf. Dis., 12(9) : 671-677.
Shah A,Nizamuddin NU,Iqbal W .2018 .Down staging of cirrhosis in all cirrhotic patients with hcv genotype 3-a infection, treated with 12-weeks triple therapy, including sofosbuvir, daclatasvir and ribavirin. InMed. Forum, 3(29) : 3.
Shahid I,Almalki WH,Ibrahim MM,Alghamdi SA,Mukhtar MH,Almalki SSR,Alhaidari MS .2018 .Characterization of in vitro inhibitory effects of consensus short interference RNAs against nonstructural 5B gene of hepatitis C virus 1a genotype. Indian J. Med, 36(4) : 494-503.
Sulkowski MS,Gardiner DF,Rodriguez-Torres M,Reddy KR,Hassanein T,Jacobson I,Lawitz E,Lok AS,Hinestrosa F,Thuluvath PJ,Schwartz H PJ .2014 .Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. New Eng. J. Med, 370(3) : 211-21.
Thrift AP,El-Serag HB,Kanwal F HB .2017 .Global epidemiology and burden of HCV infection and HCVrelated disease. Nat. Rev. Gastroenterol. Hepatol., 14(2) : 122-132.
Ullah A,Rehman IU,Ahmad J,Gohar M,Ahmad S,Ahmad B .2020 .Hepatitis-C virus and cirrhosis: An overview from Khyber Pakhtunkhwa province of Pakistan. , 33(5) : 396-403.
Ullah A,Rehman IU,Ahmad J,Odenthal M,Ahmad S,Nadeem T,Ali Q,Rizwan M,Khan MA,Hassan S,Ahsan H S .2021 .Phylogenetic analysis of the 5ʹ untranslated region of HCV from cirrhotic patients in Khyber Pakhtunkhwa, Pakistan. , 11(1) : 15023.
Wani MA,Agarwal NB,Khan MA .2022 .Neurocognitive changes in chronic hepatitis c patients receiving combination therapy of interferon and ribavirin: A systematic review. Curr Drug Ther., 17(5) : 349-358.
Welzel TM,Petersen J,Herzer K,Ferenci P,Gschwantler M,Wedemeyer H,Berg T,Spengler U,Weiland O,van der Valk M,Rockstroh J .2016 .Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. , 65(11) : 1861-70.
Zafar A,Imran M,Zahoor S,Shah ZH,Ali M,Afzal MS M .2018 .Prevalence and treatment of untypable HCV variants in different districts of Punjab, Pakistan. , 31(6) : 426-432.
Zeuzem S,Feinman SV,Rasenack J,Heathcote EJ,Lai MY,Gane E,O'Grady J,Reichen J,Diago M,Lin A,Hoffman J .2000 .Peginterferon alfa-2a in patients with chronic hepatitis C. New Eng. J. Med, 343(23) : 1666-1672.
0

Citations

0

Downloads

69

Views